Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2012

View Archived Issues

Parkinson's Disease Foundation awards grants to support research

First-in-human results show safety and immunogenicity of a novel AIDS vaccine

Researchers present results from taliglucerase alfa trials

Japanese researchers present novel GPR119 receptor agonists

Bionomics discloses new agents for CNS disorders

Merck & Co. patents novel dipeptidyl peptidase inhibitors

IRM discloses new Trk inhibitors

Phase III trial begins for theragnostic drug in patients with progressive midgut carcinoid

Baxter and Onconova enter into European licensing agreement for rigosertib

Intellikine divulges novel inhibitors of PI3Kalpha

Dompe presents new TRPM8 antagonists with potent activity in neuropathic pain models

Researchers at CSIC and the Universitat de Barcelona disclose new GSK-3 beta inhibitors

Belgian and U.S. researchers synthesize novel agents for viral infections

Urinary CCL18 assessed as a biomarker for Gaucher's disease

Bionor Pharma presents phase II results for HIV vaccine

Grifols updates on Alzheimer's disease research strategies

EB66 cell-based human influenza vaccine advances to phase III

Pharmacokinetic study of topical ketoprofen set to begin

Gamida Cell completes enrollment in phase I/II NiCord study

Phase II study begins of Zevalin in lymphoma

Health Canada approves Byetta added on to insulin glargine

Xcovery begins phase I/II trial of its angiogenesis inhibitor in wet AMD

Medivir and Janssen to conduct phase IIa trial of interferon-free combination for chronic HCV

Intellect Neurosciences and MRC Technology complete humanization of therapeutic antibody

Aerpio Therapeutics begins dosing in phase Ib/IIa trial of AKB-9778

PolyMedix receives NCI grant to study brilacidin for oral mucositis

Licensing agreement set after TXA-127 feasibility study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...